Diphtheria tetanus toxoid and pertussis third-dose (DTP3) in Afghanistan
Afghanistan: Diphtheria tetanus toxoid and pertussis third-dose (DTP3) was 61.0% in 2025. ▲ Rising
Diphtheria tetanus toxoid and pertussis third-dose (DTP3) in Afghanistan, 2000–2025
Source: World Health Organization, Global Health Observatory.
Analysis
Afghanistan recorded 61.0% for diphtheria tetanus toxoid and pertussis third-dose (dtp3) in 2025.
The figure is down 3.2% on the previous year and down 4.7% over ten years.
Over the whole period, diphtheria tetanus toxoid and pertussis third-dose (dtp3) in Afghanistan peaked at 68.0% in 2011 and was at its lowest, 24.0%, in 2000.
That places Afghanistan 183rd out of 194 countries with data for 2025, putting it in the bottom quarter.
The long-run direction has been consistently rising across the 26 years of available data.
Diphtheria tetanus toxoid and pertussis third-dose (DTP3) in Afghanistan, year by year
| Year | Value | Change |
|---|---|---|
| 2000 | 24.0% | — |
| 2001 | 33.0% | +37.5% |
| 2002 | 36.0% | +9.1% |
| 2003 | 41.0% | +13.9% |
| 2004 | 50.0% | +22.0% |
| 2005 | 58.0% | +16.0% |
| 2006 | 58.0% | +0.0% |
| 2007 | 63.0% | +8.6% |
| 2008 | 64.0% | +1.6% |
| 2009 | 63.0% | -1.6% |
| 2010 | 66.0% | +4.8% |
| 2011 | 68.0% | +3.0% |
| 2012 | 67.0% | -1.5% |
| 2013 | 64.0% | -4.5% |
| 2014 | 62.0% | -3.1% |
| 2015 | 64.0% | +3.2% |
| 2016 | 66.0% | +3.1% |
| 2017 | 64.0% | -3.0% |
| 2018 | 68.0% | +6.2% |
| 2019 | 65.0% | -4.4% |
| 2020 | 61.0% | -6.2% |
| 2021 | 55.0% | -9.8% |
| 2022 | 60.0% | +9.1% |
| 2023 | 62.0% | +3.3% |
| 2024 | 63.0% | +1.6% |
| 2025 | 61.0% | -3.2% |
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2000s | 49.0% | 24.0% | 64.0% | 10 |
| 2010s | 65.4% | 62.0% | 68.0% | 10 |
| 2020s | 60.3% | 55.0% | 63.0% | 6 |
Countries ranked near Afghanistan
More health data for Afghanistan
- Un projection of annual infant deaths, annual growth rate -1.45 % change on previous year (2100)
- Heat deaths vs projected death rates, annual growth rate 1.03 % change on previous year (2090)
- Estimated changes in temperature-related death rates compared to projected death rates 812.4 deaths per 1,000 people (2090)
- Number of infants who die before age 1 14,735 deaths (2100)
- Population ages 0-14, female, annual growth rate 2.05 % change on previous year (2025)
- Population ages 0-14, female, per unit of GDP 0.0005 units per US$ of GDP (2024)
- Population ages 0-14, female, per capita 0.2081 units per person (2025)
- Population ages 0-14, male, annual growth rate 1.99 % change on previous year (2025)
- Population ages 0-14, male, per unit of GDP 0.0005 units per US$ of GDP (2024)
- Population ages 0-14, male, per capita 0.2175 units per person (2025)
Frequently asked questions
- What is diphtheria tetanus toxoid and pertussis third-dose (dtp3) in Afghanistan?
- Diphtheria tetanus toxoid and pertussis third-dose (dtp3) in Afghanistan was 61.0% in 2025, according to World Health Organization, Global Health Observatory.
- What is the highest diphtheria tetanus toxoid and pertussis third-dose (dtp3) recorded in Afghanistan?
- The highest recorded value was 68.0% in 2011.
- What is the lowest diphtheria tetanus toxoid and pertussis third-dose (dtp3) recorded in Afghanistan?
- The lowest recorded value was 24.0% in 2000.
- How does Afghanistan rank for diphtheria tetanus toxoid and pertussis third-dose (dtp3)?
- Afghanistan ranks 183rd out of 194 countries with data for 2025.
- Is diphtheria tetanus toxoid and pertussis third-dose (dtp3) rising or falling in Afghanistan?
- Over the last ten years it is down 4.7%. The long-run trend across the full record is rising.
- Where does this Afghanistan data come from?
- The figures come from World Health Organization, Global Health Observatory, published as part of Diphtheria tetanus toxoid and pertussis third-dose (DTP3) immunization coverage among 1-year-olds (%) (WUENIC). Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 26 observations, free to reuse under CC BY-NC-SA 3.0 IGO (WHO).